Recent moves in the industry include C-suite shuffle at Armis Biopharma, plus Voyager Therapeutics acquires chief financial officer from Vor Biopharma.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
